atherobcell.eu
ATHERO-B-CELLATHERO-B-CELL: Targeting and exploiting B cell functions for treatment in cardiovascular diseases
http://www.atherobcell.eu/
ATHERO-B-CELL: Targeting and exploiting B cell functions for treatment in cardiovascular diseases
http://www.atherobcell.eu/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Sunday
LOAD TIME
0.7 seconds
PAGES IN
THIS WEBSITE
5
SSL
EXTERNAL LINKS
16
SITE IP
217.73.236.232
LOAD TIME
0.734 sec
SCORE
6.2
ATHERO-B-CELL | atherobcell.eu Reviews
https://atherobcell.eu
ATHERO-B-CELL: Targeting and exploiting B cell functions for treatment in cardiovascular diseases
atherobcell.eu
ATHERO-B-CELL
http://www.atherobcell.eu/publications.html
Targeting and exploiting B cell. Functions for treatment in. Pagano S, Carbone F, Burger F, Roth A, Bertolotto M, Pane B, Spinella G, Palombo D, Pende A, Dallegri F, Satta N, Virzi J, Fontana P, Mach F, Montecucco F, Vuilleumier N. Anti-Apolipoprotein A-1 autoantibodies as active modulators of atherothrombosis. Eur J Clin Invest. Carbone F, Bonaventura A, Liberale L, Cea M, Montecucco F. Targeting inflammation in primary cardiovascular prevention. Cole JE, Astola N, Cribbs AP, Goddard ME, Park I, Green P...
ATHERO-B-CELL
http://www.atherobcell.eu/participants.html
Targeting and exploiting B cell. Functions for treatment in. The Chancellor, Master and Scholars. Of University of Oxford. Roche Innovation Center Copenhagen A/S. Università degli Studi di Genova. University Medical Center Utrecht. ALTA Ricerca e Sviluppo in. Biotecnologie S.r.l.u.
ATHERO-B-CELL
http://www.atherobcell.eu/objectives.html
Targeting and exploiting B cell. Functions for treatment in. To define targets to reduce activation of pathogenic B cells and antibodies in Cardiovascular Diseases. To identify enhancers of atheroprotective B regulatory cell populations and antibodies in Cardiovascular Diseases. To validate molecular and miRNA targets to modulate B cell behavior in Cardiovascular Diseases with innovative locked nucleic. Acid (LNA) based antisense platforms. Project structure and organization.
ATHERO-B-CELL
http://www.atherobcell.eu/organization.html
Targeting and exploiting B cell. Functions for treatment in. Project structure and organization. To achieve these objectives Athero-B-Cell is organized in 6 Working Packages (WPs):. WP1: “Discovery of B cell specific therapeutic targets for CVD”. Will take advantage of existing large-scale clinical studies. Available to Athero-B-Cell Partners from previous FP6 and FP7-funded collaborative work to perform B cell specific high-throughput proteomics and transcriptomics (including miRNA). Verification of suc...
ATHERO-B-CELL
http://www.atherobcell.eu/focus.html
Targeting and exploiting B cell. Functions for treatment in. Aims to overcome the limitations of existing therapeutics by targeting only defined B cell subsets with specific pathogenic or regulatory functions. An experimental platform that permits the identification and selective targeting of mature B cell type(s) that either promote or prevent atherosclerosis and autoimmunity is lacking. Athero-B-Cell Project intends to identify differences in B cell effector subsets relevant to atherosclerosis. Is made...
TOTAL PAGES IN THIS WEBSITE
5
ALTA
http://www.altaweb.it/mission.html
Role and main tasks of ALTA. Why fund raising is necessary? 2010 ALTA S.r.l.u. - Via Fiorentina, 151 - 53100 Siena - Italy. Tel 39 0577 50518 fax 39 0577 593815. Capitale sociale € 10.845,00. CF 12364330154 P.IVA 01033520527.
ALTA
http://www.altaweb.it/people.html
Maria Grazia De Leon. Communication and Events Manager. 2010 ALTA S.r.l.u. - Via Fiorentina, 151 - 53100 Siena - Italy. Tel 39 0577 50518 fax 39 0577 593815. Capitale sociale € 10.845,00. CF 12364330154 P.IVA 01033520527.
ALTA
http://www.altaweb.it/news_archive.html
PROJECTS APPROVED IN THE 2015 CALL - HORIZON 2020. Health, demographic change and wellbeing:. Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of comorbidities. PROJECTS APPROVED IN THE 2015 CALL - HORIZON 2020. Innovative Training Networks (ITN) European Training Networks (ETN):. A training network for the rational design of the next generation of well-defined glycoconjugate vaccines. Probing safety of nano-objects by defining immune responses of environmental organisms. The First ...
ALTA
http://www.altaweb.it/projects.html
Founded in 1998, ALTA is now managing several international projects. In particular, ALTA is involved in research projects of the European Commission in the field of biomedicine and biotechnology. Framework Program, ALTA is directly involved in EU-funded projects as participant for management activities. 18 research projects awarded. Project value € 118.185.078. 17 PEOPLE projects awarded. Project value 19.161.055. 9 research projects awarded. Project value 70.034.208. 7 research projects awarded.
ALTA
http://www.altaweb.it/index.html
Is a service-provider company specialized in developing and managing scientific research projects. The mission of ALTA is to support research activities from the idea to the realization of project. ALTA assists in finding the proper strategy, building European Consortia and putting science in the most appropriate administrative and management framework. PROJECTS APPROVED IN THE 2016-2017 CALL - HORIZON 2020. Climate action, environment, resource efficiency and raw materials. And impact of comorbidities.
ALTA
http://www.altaweb.it/pictures.html
ALTA staff and offices. Princess Anne at the exhibition Hands for Life, Hands for Hope. 25 september 2008 - St. George's - University of London. Complesso Museale S. Maria della Scala - Siena. Mostra fotografica (5 novembre - 13 gennaio 2010). EIMID Meeting - Arc et Senans, France - (October 2008). ALTA celebrates 10 years of activity. 2010 ALTA S.r.l.u. - Via Fiorentina, 151 - 53100 Siena - Italy. Tel 39 0577 50518 fax 39 0577 593815. Capitale sociale € 10.845,00. CF 12364330154 P.IVA 01033520527.
ALTA
http://www.altaweb.it/old_projects.html
Fungi in the setting of inflammation, allergy and autoimmune diseases: Translating basic science into clinical practices. European Institute of Microbiology and Infectious Diseases. Set up and comparison of multiple stem cell approaches for kidney repair. Design of a vaccine to immunize neonates against GBS infections through a durable maternal immune response. European Vaccines and Microbicides Enterprise. New preventative and therapeutic Hepatitis C vaccines: from pre-clinical to phase 1. New carbohydr...
ALTA
http://www.altaweb.eu/news_archive.html
PROJECTS APPROVED IN THE 2015 CALL - HORIZON 2020. Health, demographic change and wellbeing:. Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of comorbidities. PROJECTS APPROVED IN THE 2015 CALL - HORIZON 2020. Innovative Training Networks (ITN) European Training Networks (ETN):. A training network for the rational design of the next generation of well-defined glycoconjugate vaccines. Probing safety of nano-objects by defining immune responses of environmental organisms. The First ...
TOTAL LINKS TO THIS WEBSITE
16
Australian Atherosclerosis Society
2017 AAS Annual Scientific Meeting. ASM (AAS, HBPRCA and AVBS) – Hobart Dec 2016. Immuno-Metabolic Mechanisms of Atherosclerosis. 3rd World Congress in Clinical Lipidology. Webinars & Meetings. Australian Atherosclerosis Society is the premier society for Atherosclerosis research and education in Australia. Read all about the 2017 ASM and the award winners HERE. This year we will once again be joining. Read More ». 2017 AAS Annual Scientific Meeting – report. Read More ».
中国动脉硬化网
黎 健 杨向红 叶 平. 王贵学 秦树存 朱 力. 阮长耿 张 运 陈 琪. 重视加强 医师定期考核 医德 工作. 第十三次全国动脉硬化性疾病学术会议通知 第一轮 由中国病理生理学会动脉粥样硬化专业委员会、国际动脉粥样硬化学会中国分会和 中国动脉硬化杂志 编辑部主办，重庆大学、重庆市人民. Preliminary Program of Canada. The Second Announcement of C. Preliminary Program of Canada. The Second Announcement of C. 版权所有 2013 中国动脉硬化网 地址 湖南省衡阳市蒸湘区常胜西路28号 南华大学心血管疾病研究所. E-mail:capas cn@163.com 联系电话 07348281279.
Athero.ru - "Сайт центра атеросклероза"
Большинство причин заболеваний сердца нам известны. Ключевая проблема настоящего времени - применение того, что мы знаем, для предупреждения преждевременных болезней сердца. Лаборатория клинической кадиологии и Центр атеросклероза были созданы в НИИ физико-химической медицины в 1989 г. В 1994-2015 гг они работали на базе ГКБ 29. Центр атеросклероза прекратил существование в середине 2015 г. Лаборатория клинической кардиологии (1989-2015). Руководитель в 1989-2015 гг Н.А. Грацианский. Of course, those who...
Blog de athero - c est moi mustafa - Skyrock.com
Mot de passe :. J'ai oublié mon mot de passe. C est moi mustafa. Je mappelle mostafa je suis de 24ans je suis un marocain je habite au maroc jaimerais de fond conni une fille qui un coeur gentil serieuse pour faire la vie. Mise à jour :. Cette une de me soirre au maroc. Abonne-toi à mon blog! Voila le style chanson cha3bi algerie avec en costume noir. Ou poster avec :. Retape dans le champ ci-dessous la suite de chiffres et de lettres qui apparaissent dans le cadre ci-contre. Ou poster avec :. Retape dan...
athero2015.com
Athero2015.com is not available due to technical maintenance. Athero2015.com is niet beschikbaar i.v.m. technisch onderhoud. 19-5-2015 • athero2015.com.
ATHERO-B-CELL
Targeting and exploiting B cell. Functions for treatment in. The treatment of risk factors, albeit beneficial, has reached its full potential in CVD and new treatments should be targeted to novel disease factors. Inflammation is the important component of the pathogenesis of CVD that is not yet therapeutically targeted. B cells are a classic example of the contrasting role of immune cell subsets in CVD. Harnessing protective or abating unwanted B cell responses has the potential to shed light on the path...
Blog de atherock - Athé... - Skyrock.com
Mot de passe :. J'ai oublié mon mot de passe. Plus d'actions ▼. S'abonner à mon blog. Création : 07/08/2009 à 17:29. Mise à jour : 13/07/2011 à 16:10. Ben pas besoin . Si tu vois vraiment qui je suis ben t'as tout compris :). Si pas ben tampis et part. Un jour on aime, un jour on trahi ou on est trahi, un jour on pardonne, un jour on est mal, un jour on veut mourir, un jour on est heureux, un jour on se sent mieux, mais quand on est mal de vrais amis sont là pour nous! Ou poster avec :. Retape dans le ch...
Renal Remission & Hypertension Clinic
Coming Soon - Future home of something quite cool
Future home of something quite cool. If you're the site owner. To launch this site. If you are a visitor. Please check back soon.
お医者さんのサプリメント（ＥＰＡ、ＤＨＡ、発酵穀類、プロポリス） | お医者さんが考案したアテロカットは、動脈硬化の予防に推奨されているEPA，DHAに天然の抗生物質といわれるプロポリスやビタミンの豊富な大豆・玄米・鳩麦を発酵させて作り出した多種類の酵素および、緑茶や小麦胚芽などを加えた栄養補助食品です。
EPA、DHAってなに それは、一言でいうと お魚の脂 のことです。
ATHERO-FLUX
Lipid lowering has significantly reduced cardiovascular disease. CVD) mortality in EU. However, the aim to abolish CVD in EU is far from achieved and attempts to improve on the benefits of statins with new agents have not yet delivered new therapeutics. The Consortium Athero-Flux. Builds on FP7-generated large-scale lipidomics data. Showing that specific sphingolipids (SLs). A better primary and secondary prevention of CVD events than with statins alone can be achieved. 21-23 September, Siena. The Chance...
